Moringa Acquisition Corp (MACAU)
Price:
9.90 USD
( - -1.90 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Agriculture & Natural Solutions Acquisition Corporation
VALUE SCORE:
6
2nd position
Melar Acquisition Corp. I
VALUE SCORE:
11
The best
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Moringa Acquisition Corp does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It focuses on pursuing opportunities in technology-based businesses or industries in Israel. The company was incorporated in 2020 and is based in New York, New York.
NEWS
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
globenewswire.com
2024-02-22 08:27:00Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion's pre-transaction equity value to be $62.5 million, based on a $10 share price.
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
globenewswire.com
2023-08-15 09:25:00New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa” or the “Company”) announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on August 16, 2023 (the “Extraordinary Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination (the “Extension”) from August 19, 2023 (the “Current Termination Date”) to August 19, 2024 or such earlier date as may be determined by the Company's board of directors, in its sole discretion (such new termination date, the “Extension Date”), the Company's sponsor, Moringa Sponsor, L.P., and/or its wholly-owned subsidiary Moringa Sponsor (US) L.P. (collectively, the “Sponsor”), or the Sponsor's designees, will make additional contributions to the Company's trust account following the approval and implementation of the Extension.
No data to display
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
globenewswire.com
2024-02-22 08:27:00Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion's pre-transaction equity value to be $62.5 million, based on a $10 share price.
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
globenewswire.com
2023-08-15 09:25:00New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa” or the “Company”) announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on August 16, 2023 (the “Extraordinary Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination (the “Extension”) from August 19, 2023 (the “Current Termination Date”) to August 19, 2024 or such earlier date as may be determined by the Company's board of directors, in its sole discretion (such new termination date, the “Extension Date”), the Company's sponsor, Moringa Sponsor, L.P., and/or its wholly-owned subsidiary Moringa Sponsor (US) L.P. (collectively, the “Sponsor”), or the Sponsor's designees, will make additional contributions to the Company's trust account following the approval and implementation of the Extension.